化疗及非化疗组神经母细胞瘤干细胞标志物的表达及意义

Expression of stem cell makers in chemotherapy and non-chemotherapy neuroblastoma

目的探讨干细胞标志物CD133、ABCG2、CD117及nestin在神经母细胞瘤化疗组及非化疗组患儿中的表达及意义。方法收集上海交通大学附属新华医院小儿外科保存完好的20例神经母细胞瘤肿瘤组织的石蜡标本，按术前是否经历化疗分为术前化疗组和未化疗组，每组各10例，采用免疫组化SupperVision法检测4种标记物在肿瘤组织中的表达。结果CD133、ABCG2、CD117及nestin干细胞标志物在未化疗神经母细胞瘤组织中的平均阳性细胞率低于化疗后残留神经母细胞瘤组织中阳性细胞率的平均值，差异无统计学意义（P〉0．05）。两组患儿年龄、性别、分期及组织分型比较，差异无统计学意义（P〉0．05）。结论儿童神经母细胞瘤中可能存在肿瘤干细胞，肿瘤干细胞对常规化疗药物具有耐药性。

Objective To investigate the expression of stem cell makers CD133,ABCG2,CD117 and nestin in neuroblastoma before and after chemotherapy and their significane. Methods The paraffin sections of 20 cases managed in our hospital were divided into pre-operative chemotherapy group （10 cases）and non-ehemotherapy group（ 10 cases）. The expressions of four markers were immunohistochemieally detected in the samples. Results There was no significant difference of the expressions intensity of CD133,ABCG2,CD117 and nestin between the two groups of specimens （ P 〉 0.05）. In non-chemotherapy and pre-operative chemotherapy neuroblastoma, the expression intensity of CD133 ,ABCG2,CD117 and nestin showed no significant correlation with patients, sex, age,tissue type or tumor stage （ all P 〉 0.05 ）. Conclusions Tumor stem cells might exist in neuroblastoma tissue. Tumor stem cells are resistant to conventional chemotherapy.